Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery

Alzheimer's and Dementia

Volumn 2, Issue 4, 2006, Pages 275-281

  Schenk, Dale ^a   Carrillo, Maria C ^b   Trojanowski, John Q ^c  

^a ELAN PHARMACEUTICALS   (United States)

^b ALZHEIMER'S ASSOCIATION   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dementia; Environmental enrichment; GSK3; Neurofibrillary tangle; Tau

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOSINE TRIPHOSPHATE; ALPHA SECRETASE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN; APOLIPOPROTEIN E; ASCORBIC ACID; BETA SECRETASE INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL; CURCUMIN; CYCLIN DEPENDENT KINASE 5; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GONADOTROPIN; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; NITRIC OXIDE; PRESENILIN 1; PRESENILIN 2; PROTEASOME; PROTEINASE; ROSIGLITAZONE; UBIQUITIN; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CYTOSKELETON; DISEASE COURSE; DRUG RESEARCH; ENVIRONMENTAL FACTOR; GENE IDENTIFICATION; GENE MUTATION; HUMAN; MEDICAL RESEARCH; NEUROFIBRILLARY TANGLE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SENILE PLAQUE;

EID: 33749533006     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.08.005     Document Type: Article

References (27)

1. Siemers E.R. Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease". Alzheimer's & Dementia 2 (2006) 140-142
2. Mohs R.C., Kawas C., and Carrillo M.C. Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimer's & Dementia 2 (2006) 131-139
3. Skovronsky D.M., Lee V.M., and Trojanowski J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech 1 (2006) 151-170
4. Lee V.M.-Y., and Trojanowski J.Q. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. Journal of Alzheimer's Disease, Supplement: Alzheimer's Disease: A Century Of Scientific and Clinical Research 9 3-Supp (2006) 257-262
5. Jedrziewski M.K., Lee V.M.-Y., and Trojanowski J.Q. Lowering the risk of Alzheimer's disease: evidence-based practices emerge from new research. Alzheimer's & Dementia 1 (2005) 152-160
6. Bhat R.V., Budd Haeberlein S.L., and Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. Journal Neurochem 89 6 (2004) 1313-1317
7. Ahn J.S., Radhakrishnan M.L., Mapelli M., Choi S., Tidor B., Cuny G.D., et al. Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol 12 7 (2005) 811-823
8. Kraemer B.C., Zhang B., Beverenz J.B., Thomas J.H., Trojanowski J.Q., and Shellengberg G.D. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100 17 (2003) 9980-9985
9. Dickey C.A., Dunmore J., Lu B., Wang J., Lee W.C., Kamal A., et al. HSP induction mediates selective clearance of tau phosphorylated at praline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 6 (2006) 753-755
10. Kuret J., Congdon E.E., Li G., Yin H., Yu X., and Zhong Q. Evaluating triggers and enhancers of tau fibrillization. Microsc Res Tech 67 3-4 (2005) 41-55
11. Trojanowski J.Q., Smith A.B., Huryn D., and Lee V.M. Microtubule-stabilizing drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Exp Opin Pharmacother 6 5 (2005) 683-686
12. Ballatore C., Aspland S.E., Castillo R., Desharnais J., Eustaquio T., Sun C., et al. A facile route to paclitaxel C-10 Carbamates. Bioorg Med Chem Lett 15 10 (2005) 2477-2480
13. Pedrini S., Carter T.L., Prendergast G., Petanceska S., Ehrlich M.E., and Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLOS Med 2 1 (2005) 69-78
14. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 7 11 (2005) 1118-1123
15. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L., Browne P., et al. Atorvastatin for the treatment of mild to moderate Alzheimer's disease. Arch Neurol 62 (2005) 754-757
16. Hey-Hadavi J. Commentary on "Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery." Atorvastatin's effect in Alzheimer's dementia (LEADe) study. Alzheimer's & Dementia 2 (2006) 282-283
17. Milgram N.W., Head E., Zicker S.C., Ikeda-Douglas C.J., Murphey H., Muggenburg B., et al. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year study. Neurobiol Aging 26 (2005) 77-90
18. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., and Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Current Alzheimer's Research 2 2 (2005) 131-136
19. Lee J., Duan W., Long J.M., Ingram D.K., and Mattson M.P. Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J Mol Neurosci 15 (2005) 99-108
20. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
21. Bennett B.M., Reynolds J.N., Prusky G.T., Douglas R.M., Sutherland R.J., and Thatcher G.R. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacology (2006) Mar 8; [Epub ahead of print]
22. Roses A.D., and Saunders A.M. Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimer's & Dementia 2 (2006) 59-70
23. Lazarov O., Robinson J., Tang Y., Aristón I.S., Korade-Mirnics Z., Lee V.M.-Y., et al. Environmental enrichment reduces AB levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-773
24. Jankowsky J.L., Melnikova T., Fadale D.J., Xu G.M., Slunt H.H., Gonzales V., et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 25 21 (2005) 5217-5224
25. Milgram N.W., Zicker S.C., Head E., Muggenburg B.A., Murphey H., Ikeda-Douglas C.J., et al. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 23 (2002) 737-745
26. Wilson R.S., Arnold S.E., Schneider J.A., Kelly J.F., Tang Y., and Bennett D.A. Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology 27 (2006) 143-153
27. Gregory C.W., Atwood C.S., Smith M.A., and Bowen R.L. Antigonadotropins: a novel strategy to halt Alzheimer's disease progression. Curr Pharm Des 12 (2006) 685-690